Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023
Company raised $30 million in gross proceeds from registered direct offering
Related news for (GRTX)
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals
- Galera Announces Board Approval of Complete Liquidation and Dissolution
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
- Galera Adopts Limited Duration Stockholder Rights Agreement
- Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates